Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety.

@article{Gianturco2013ImpactOC,
  title={Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety.},
  author={Vincenzo Gianturco and Giovanni Troisi and Alessia Bellomo and Sciaila Bernardini and Elisa D'Ottavio and Valeria Formosa and Cristina Lo Iacono and Walter Verrusio and Benedetta Marigliano and Vincenzo Marigliano},
  journal={Hepatology international},
  year={2013},
  volume={7 2},
  pages={
          570-6
        }
}
BACKGROUND AND PURPOSE Nonalcoholic fatty liver disease (NAFLD) is one of the causes of a fatty liver, occurring when fat is deposited (steatosis) in the liver not due to excessive alcohol use. It is related to insulin resistance and the metabolic syndrome. The purpose of the present study was to evaluate the impact of combination therapy with alpha-lipoic acid (ALA) and ursodeoxycholic acid (UDCA) on NAFLD. METHODS Alpha-lipoic acid 400 mg/day plus UDCA 300 mg/day (ALAUDCA) was investigated… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

DE Kleiner, EM Brunt, M Van Natta
  • Hepatology
  • 2005
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Predictive validity of a medication adherence measure for hypertension control

DE Morisky, A Ang, M Krousel-Wood
  • J Clin Hypertens (Greenwich)
  • 2008
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…